tbuckley/cabot-search huggingface dataset:
P07.16 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation
Authors: B. Suchorska, A. Biczok, M. Lenski, N. L. Albert, U. Schüller, J. Tonn
Journal: Neuro-Oncology (2016)

AbstractBackground:Contrast enhancement (CE) and anaplasia have been reported to indicate poor outcome in diffuse glioma. Recently, mutational status of the IDH1/2 gene and loss of heterozygosity on chromosome 1p/19q (LOH1p/19q) have gained relevance for the evaluation of clinical outcome. Currently, a three-way classification based on IDH1/2 mutation and LOH 1p/19q has gained further importance and will eventually supersede the current WHO grading system in terms of risk stratification and treatment planning. Thus, we aimed in the present study to re-evaluate CE and histopathological WHO grading as risk factors for survival within the framework of these molecular markers.Methods:332 patients with diffuse glioma WHO grade II (n=189) or grade III (n=143) were stratified into 3 groups: IDH1/2 wild type (n=118), IDH1/2 mutated with (n=123) and without (n=91) LOH1p/19q. Preoperative magnetic resonance (MR) imaging was reviewed for presence of CE. Univariate and multivariate analyses were conducted taking into account CE, WHO grading, molecular as well as age, Karnofsky performance status, surgical procedure and adjuvant therapy.Results:In multivariate analysis, CE was not associated with OS in IDH1/2 wild type tumors whereas histopathological WHO grading had a strong independent prognostic value on OS in (p=0.001). In gliomas with IDH1/2 mutation, CE independently predicts shorter survival (p=0.04) and this effect seems to be especially pronounced in the IDH1/2 mutated group without LOH 1p/19q.Conclusions:In patients with diffuse gliomas WHO grade II/III and IDH1/2 wildtype, CE is not associated with survival in contrast to WHO grading. In patients with an IDH1/2 mutation, presence of CE on initial MRI is linked to inferior survival while grading is not.
Case 6-2017
Authors: Paul A. Monach, John H. Stone, Amita Sharma, Rosalynn M. Nazarian
Journal: New England Journal of Medicine (2017)

A 57-year-old woman presented with fatigue, night sweats, weight loss, headache, abdominal pain, and skin lesions. Laboratory testing revealed hypergammaglobulinemia and hypocomplementemia. Diagnostic tests were performed.
Paraneoplastic pemphigus associated with Castleman disease: progression from mucous to mucocutaneous lesions with epitope-spreading phenomena
Authors: K. Okahashi, N. Oiso, N. Ishii, M. Miyake, S. Uchida, H. Matsuda, M. Kitano, J. Hida, S. Kawai, A. Sano, T. Hashimoto, A. Kawada
Journal: British Journal of Dermatology (2017)

Paraneoplastic pemphigus (PNP) is a frequently fatal autoimmune blistering disease of the skin and mucous membranes.1 PNP is commonly associated with malignant neoplasms or haematological disorders like Castleman disease (CD). The eruptions may resemble those seen in various other conditions such as lichen planus (LP), graft-versus-host disease, erythema multiforme (EM), bullous pemphigoid and pemphigus vulgaris (PV).2

This article is protected by copyright. All rights reserved.
Placenta Derived Adherent Cells (PDACs) Suppress Tumor Cells of Diverse Origin.
Authors: Ryhor Harbacheuski, Casper Paludan, Rose Ann Murray, Megan Mendillo, Jorge Soler, Jia-Lun Wang, Qian Ye, Wolfgang Hofgartner, James Edinger, Gilla Kaplan, Robert Hariri
Journal: Blood (2006)
Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Authors: C. Zielinski, J. Gligorov, N. Marschner, F. Puglisi, E. Vrdoljak, J. Cortes Castan, S. de Ducla, R. Deurloo, V. Easton, G. von Minckwitz
Journal: Annals of Oncology (2016)
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018): An interim report
Authors: K. Yamada, T. Shimokawa, H. Okamoto, H. Tanaka, K. Kubota, K. Kishi, H. Saitho, Y. Takiguchi, Y. Hosomi, T. Kato, D. Harada, N. Masuda, T. Kasai, Y. Nakamura, K. Minato, T. Kaburagi, K. Naoki, K. Hikino, T. Yamanaka, K. Watanabe
Journal: Annals of Oncology (2016)
Allogeneic Hematopoietic Stem Transplantation Does Not Erase the Impact of the New Prognosis Classification in AML and the Negative Influence of Evi1 and Flt3 ITD Mutations.
Authors: Mauricette Michallet, Mohamad Sobh, Sandrine Hayette, Carole Charlot, Mohamed El Hamri, Nathalie Tedone, Franck Emmanuel Nicolini, Giovanna Cannas, Youcef Chelghoum, Emmanuelle Nicolas-Virelzier, Sophie Ducastelle, Fiorenza Baracco, Isabelle Tigaud, Xavier Thomas
Journal: Blood (2009)
ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143
Authors: Antonio Omuro, Gordana Vlahovic, Joachim Baehring, Nicholas Arthur Butowski, David A. Reardon, Timothy Cloughesy, Solmaz Sahebjam, Michael Lim, Lewis Strauss, Robert Latek, Ricardo Zwirtes, Prashni Paliwal, Chris Harbison, John Sampson
Journal: Neuro-Oncology (2016)

Patients with glioblastoma have a poor prognosis, with 5-year survival rates <5%. Nivolumab is an IgG4 monoclonal antibody inhibitor of programmed death 1 (PD-1) receptor with demonstrated efficacy in multiple cancer types. In phase 1 cohorts 1c and 1d of CheckMate 143 (NCT02017717), the safety and tolerability of nivolumab with radiotherapy ± temozolomide was evaluated in patients with newly diagnosed glioblastoma. Following surgery, patients in cohort 1c received nivolumab 3 mg/kg Q2W with standard radiotherapy and temozolomide concurrently (75 mg/m2 daily), and then with adjuvant temozolomide (150–200 mg/m2 for 5 days/28 days for ≥6 cycles). Cohort 1d patients had unmethylated MGMT and received nivolumab 3 mg/kg Q2W with radiotherapy and no temozolomide. Nivolumab was continued Q2W for patients in both cohorts until progression/unacceptable toxicity. Most patients (61%) in cohorts 1c (n=31) and 1d (n=26) had measurable disease at enrollment. In cohort 1c, 39% and 52% of patients had methylated and unmethylated MGMT promoters, respectively. To date (cutoff, 3/23/2016), treatment has been well tolerated. Treatment discontinuation in cohorts 1c (26%) and 1d (35%) was due primarily to radiographic progression (1c, 10%; 1d, 35%) and withdrawn consent (1c, 10%). Most frequent treatment-related adverse events (AEs) included fatigue (1c, 1d: 26%, 23%), headache (23%, 8%), and increased AST (23%, 0%). Treatment-related serious AEs reported in ≥2 patients were pneumonia (6%, 0%), pyrexia (6%, 0%) and tumor flare (3%, 8%), characterizing either disease progression or pseudoprogression. AEs leading to discontinuation were increased aminotransferases (n=2 [1c]). No toxic deaths have been reported. This is the first prospective clinical trial investigating nivolumab in newly diagnosed glioblastoma. Results suggest that the combination of nivolumab with radiotherapy ± temozolomide is feasible and well tolerated, raising no new safety concerns. These data support continued clinical investigation in this population. Updated efficacy results will be presented
Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial
Authors: G.D. Demetri, P. Reichardt, Y.-K. Kang, J.-Y. Blay, H. Joensuu, C. Kappeler, C. Wuchter-Czerwony, J. Chung, A. Wagner, P.G. Casali
Journal: Annals of Oncology (2016)
Effects of abiraterone in Japanese men with metastatic castration-resistant prostate cancer after enzalutamide treatment
Authors: Hiroyuki Iio, Keito Shiozaki, Kisuke Ozaki, Takuya Tsujioka, Kennichi Nishimura, Shirou Fujikata, Shuuji Tanimoto, Kenjirou Okamoto, Sadamu Yamashi, Masaharu Kan
Journal: Annals of Oncology (2016)
High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age&gt;60) High Risk Patients with Acute Myeloid Leukemia (AML)
Authors: Muthalagu Ramanathan, Zheng Zhou, Jan Cerny, Glen D Raffel, Laura Petrillo-Deluca, William Vincent Walsh, Venu Bathini, Micheal Vail, Karen Smethers, Bruce Woda, Patricia Miron, Alan G. Rosmarin, Rajneesh Nath
Journal: Blood (2010)
Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study
Authors: Kirsten Rozemeijer, Steffie K Naber, Corine Penning, Lucy I H Overbeek, Caspar W N Looman, Inge M C M de Kok, Suzette M Matthijsse, Matejka Rebolj, Folkert J van Kemenade, Marjolein van Ballegooijen
Journal: BMJ (2017)

Objective To compare the cumulative incidence of cervical cancer diagnosed within 72 months after a normal screening sample between conventional cytology and liquid based cytology tests SurePath and ThinPrep.Design Retrospective population based cohort study.Setting Nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA), January 2000 to March 2013.Population Women with 5 924 474 normal screening samples (23 833 123 person years).Exposure Use of SurePath or ThinPrep versus conventional cytology as screening test.Main outcome measure 72 month cumulative incidence of invasive cervical cancer after a normal screening sample for each screening test. Cox regression analyses assessed the hazard ratios, adjusted for calendar time, age, screening history, and socioeconomic status and including laboratories as random effects.Results The 72 month cumulative cancer incidence was 58.5 (95% confidence interval 54.6 to 62.7) per 100 000 normal conventional cytology samples, compared with 66.8 (56.7 to 78.7) for ThinPrep and 44.6 (37.8 to 52.6) for SurePath. Compared with conventional cytology, the hazard of invasive cancer was 19% lower (hazard ratio 0.81, 95% confidence interval 0.66 to 0.99) for SurePath, mainly caused by a 27% lower hazard (0.73, 0.57 to 0.93) of a clinically detected cancer. For ThinPrep, the hazard was on average 15% higher (hazard ratio 1.15, 0.95 to 1.38), mainly caused by a 56% higher hazard of a screen detected cancer (1.56, 1.17 to 2.08).Conclusions These findings should provoke reconsideration of the assumed similarity in sensitivity to detect progressive cervical intraepithelial neoplasia between different types of liquid based cytology and conventional cytology.
Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?
Authors: Ryan T. Groeschl, Sam G Pappas, Kathleen K. Christians, Susan Tsai, Edward J Quebbeman, T. Clark Gamblin, Kiran Turaga
Journal: Journal of Clinical Oncology (2012)

256 Background: Although transplantation has shown remarkable survival benefit for patients with hepatocellular carcinoma (HCC), there is limited data to support or refute the treatment of combined hepatocellular-cholangiocarcinoma (cHCC-CC) with transplantation. We hypothesized that patients with mixed histology had a lower overall survival than HCC after liver transplantation. Methods: Patients with localized HCC and cHCC-CC treated with surgical resection (SR) or transplant (TP) were identified using the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2007). Survival was analyzed using the Kaplan-Meier model. Prognostic factors were examined with Cox regression analyses. Results: We identified 3378 (1447 [43%] TP and 1931 [57%] SR) patients with HCC, and 54 (19 [35%] TP and 35 [65%] SR) patients with cHCC-CC. Cohorts were similar with respect to age, gender, race, and tumor size. Median overall survival (OS) was 68 months (95% confidence interval (CI): 64-75) for HCC and 36 months (95% CI: 19-89) months for cHCC-CC (p = 0.01). Patients undergoing SR of HCC and cHCC-CC had similar 3-year OS (55% vs. 46%, p=0.4). Overall 3-year survival of patients undergoing TP was significantly longer for HCC (78%) than for cHCC-CC (48%, p=0.01). After adjusting for age at diagnosis and gender, multivariate modeling revealed an increased hazard ratio for patients undergoing TP with a mixed histology: HR 2.5 (95% CI: 1.2-5.1, p=0.01). Conclusions: Patients undergoing transplantation with localized cHCC-CC have a shorter overall survival than patients with HCC. In an era of organ shortage, this may justify excluding patients with cHCC-CC from transplantation. Our data is limited by the lack of tumor and host-specific factors, and prospective validation of this conclusion is warranted.
Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.
Authors: Stefanie Sarantopoulos, Kristen E. Stevenson, Haesook T. Kim, Nazmim S. Bhuiya, Corey S. Cutler, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz
Journal: Blood (2007)
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Authors: G. Perkins, E. Fabre, V. Fallet, H. Blons, N. Pecuchet, V. Gounant, L. Gibault, E. Michel-Jeljeli, M. Antoine, E. Roux, M. Wislez, D. Le Corre, K. Leroy, R. Lacave, J. Taieb, J. Cadranel, P. Laurent-Puig
Journal: Annals of Oncology (2016)
Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT).
Authors: F. Lennie Wong, Alysia Bosworth, Rose Danao, Doojduen Villaluna, Sunita Patel, Marcia Grant, Stephen J Forman, Smita Bhatia
Journal: Blood (2009)
P10.07 Sialate O-acetylesterase (SIAE) over-expression leads to a collapse of the mitochondrial membrane potential and predisposes cells to etoposide treatment in RES256 medulloblastoma cells
Authors: R. L. Mather, K. F. Loveson, L. K. Donovan, G. J. Pilkington, H. L. Fillmore
Journal: Neuro-Oncology (2016)
JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma
Authors: Antonio Solimando, Andreas Brandl, Mattenheimer Katharina, Carolin Graf, Miriram Ritz, Anna Ruckdeschel, Thorsten Stühmer, Martina Rudelius, Maria Antonia Frassanito, Rosenwald Andreas, Franz Jakob, Angelo Vacca, Hermann Einsele, Andreas Beilhack
Journal: Blood (2016)
The JAK2V617F Mutation in Non-MPD Hematopoiesis Occurs at a Low Frequency and in Differentiating Erythroid Cells.
Authors: Svetlana Krichevsky, Evgenia Prus, Julia Abramowitz, Aliza Treves, Ido Weinberg, Ariel Borohovitz, Riki Perlman, Eitan Fibach, Dina Ben- Yehuda
Journal: Blood (2008)
EXTH-01. OVEREXPRESSION OF Ezh2 AS A TARGET IN TREATMENT OF GLIOMA
Authors: Faris Farassati, Warner Peng, Darren Lovick, Kushal Shah, Brandon Ricke
Journal: Neuro-Oncology (2016)

Enhancer of zeste homologue 2 (Ezh2), as the catalytically active component of the Polycomb Repressive Complex 2, is involved in transcriptional repression of certain genes by trimethylation of lysine 27 and lysine 9 of histone H3. A range of human tumors show overexpression of Ezh2, which is associated with poor prognosis. Ezh2 is involved in the biology of stem cells and is thought to be a stem cell specific oncogene. Oncolytic viruses are a novel family of anti-cancer agents capable of targeting cancer. Phase I-II clinical trials using conditionally-replicating Herpes Simplex Virus Type 1 (HSV-1) have provided promising results. We have developed the first proto-type of a mutated HSV-1 which is programmed to specifically replicate in tumor cells that overexpress Ezh2. This virus is called the “Signal-Smart 3” (SS3) virus. Our team has shown significant Ezh2 expression in a multitude of tumors including but not limited to brain, breast, lung, liver, and head and neck tumors. SS3 has also been quite successful in targeting stem cells in vitro and in vivo, suppressing both viability and invasiveness. One of the more prominent tumors affected by the SS3 virus is glioblastoma.
Five-year analysis of hypersensitivity to oxaliplatin (OXP): Determination of incidence and identification of risk factors
Authors: B. H. Kim, T. P. Bradley, J. Y. Tai, D. R. Budman
Journal: Journal of Clinical Oncology (2008)

2539 Background: Hypersensitivity is a well-known complication of the platinum agents cisplatin and carboplatin. Although hypersensitivity to OXP has been increasingly recognized, the incidence reported in the literature has varied significantly. Additionally, risk factors for developing these reactions specifically to OXP have never been investigated. Here we report the incidence of hypersensitivity to OXP over a 5-year period at North Shore University Hospital, and investigate patient and disease characteristics associated with their occurrence. Methods: Information on all patients treated with OXP between September 2002 and August 2007 was retrospectively reviewed. Data from patients who experienced hypersensitivity was further analyzed and compared to those who did not have reactions. Potential risk factors investigated included sex, diagnosis, disease stage, presence of pre-existing allergies, chemotherapy received, and use of OXP in front-line vs. higher therapy. Chi-square testing was used to analyze all factors. Results: 247 patients received OXP, with 29 experiencing hypersensitivity, for an incidence of 11.7% (95% CI 7.7–15.8). Grade 3/4 events occurred in 1.6%. Only 1 of 29 patients had not been pre-treated with dexamethasone for anti-emesis. Events occurred more frequently in females (17.2% females vs 6.4% males, p=0.03) and with use of OXP as second-line or higher therapy (25.6% second-line or higher vs 9.3% front-line, p=0.01). No other characteristic demonstrated a predisposition towards these events. Conclusions: Our data set, the largest number yet recorded in the literature, demonstrates an incidence of hypersensitivity to OXP of 11.7%, with grade 3/4 events in 1.6%, values that cannot be considered rare. As use of this agent becomes more widespread increased vigilance for this potentially serious complication should be high, especially amongst female patients and with use of OXP in second-line or higher therapies, two newly recognized risk factors. Patient and Disease Characteristics In Patients Treated with Oxaliplatin Characteristics Patients with Hypersensitivity Reactions P-Value N with Hypersensitivity/ Total Patients % Sex 0.03 Female 21/122 17.2 Male 8/125 6.4 Allergies 0.80 Present 10/69 14.5 Absent 19/167 11.4 Stage 0.68 II or III 10/98 10.2 IV 19/135 14.1 Treatment Line 0.01 First 18/194 9.3 Second or higher 11/43 25.6 Diagnosis 0.47 Colon 20/142 14.1 Rectum 3/42 7.1 Other 6/42 14.3 Treatement Regimen 0.80 FOLFOX 13/111 11.7 XELOX 3/21 14.3 Any bevacizumab-containing therapy 8/51 15.7 Other 5/52 9.6 No significant financial relationships to disclose.
NCOG-17. EVALUATION OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH CEREBELLAR MEDULLOBLASTOMA
Authors: Rebecca A. Harrison, Jason M. Johnson, Catherine M. Sullaway, Jeffrey S. Wefel
Journal: Neuro-Oncology (2016)

While traditionally considered a structure of motor control, the role of the cerebellum in neurocognitive and affective processing has been increasingly recognized. In neuro-oncology, studies of neurocognitive function (NCF) in patients with cerebellar tumors have largely focused on children, and the full clinical impact of these tumors in adults remains poorly defined. The purpose of this retrospective analysis is to evaluate NCF in a predominantly adult cohort with cerebellar medulloblastoma (CM). Retrospective review of patients with CM who had received formal neuropsychological evaluation (NCE) as an adult (N=30) was conducted. Patients’ demographic, medical, and treatment histories were extracted from the medical record. Lesion dimensions were measured on MRI. Exploratory analyses examined the relationship between lesion size, location, and prior therapies with NCF. Mean age of the patient sample was 31 years (SD=11) at time of CM diagnosis. The mean time from diagnosis to NCE was 79 months (SD=144). Prior therapy included surgery (86.7%), radiation (63.3%), and chemotherapy (30.0%). On average, patients demonstrated greatest deficit in domains of processing speed (mean z = -0.83), executive function (mean z = -1.93), and memory (mean z = -1.41). Larger anterior-posterior lesion diameter was associated with worse memory (p=0.042). A history of identified hydrocephalus was associated with better memory (p=0.023), executive functioning (p=0.026), and visuospatial function (p=0.030). Prior surgical resection was associated with impaired verbal reasoning (p=0.007) and receptive language (p=0.048). Prior radiation therapy was associated with worse memory (p=0.015) and fine motor coordination (p=0.048), and prior chemotherapy with worse memory (p=0.006) and executive function (p=0.016). While lesions in the cerebellum are not classically associated with neurocognitive dysfunction, this retrospective analysis demonstrates significant neurocognitive dysfunction in a cohort of patients with predominantly adult CM. Increased study is warranted to more fully characterize the clinical impact of CM and its treatments in our patients.
Psychometric properties of the functional assessment for chronic illness therapy-spiritual wellbeing (FACIT-Sp) and its relationship wtih quality of Life on patients with non-metastatic resected cancer
Authors: C. Beato Zambrano, C. Calderón, P. Jimenez Fonseca, A. Carmona-Bayonas, T. García, A. Ramchandani, M.D.M. Muñoz, B. Castelo, E. Martinez de Castro, M.D. Fenor, J. Rogado Revuelta, M. Mangas Izquierdo, M.Á Vicente, I. Ghanem, A. Fernández, A. Padilla, M.P. Solis Hernandez, O. Donnay, M.D.M. Soriano, C. Jara
Journal: Annals of Oncology (2016)
Cobimetinib plus vemurafenib to treat unresectable or metastatic melanoma: Data from the French temporary authorization for use
Authors: N. Meyer, D.-M. Anne-Bénédicte, B. Dreno, C. Lebbe, O. Zehou, A. Gorana, M. Mouri, A. Bardet, M. Moreau, C. Mateus
Journal: Annals of Oncology (2016)
Pre-Transplant T-Cell Lymphopenia Accelerates Early Donor T-Cell and Myeloid Chimerism but Is Not Required for Full Donor Lymphohematopoietic Engraftment or To Prevent Graft Rejection Following Nonmyeloablative Hematopoietic Cell Transplantation (NST).
Authors: Shivani Srivastava, Bipin N. Savani, N. Geller, C. Carvallo, Ramaprasad Srinivasan, Y. Takahashi, A. Lundqvist, R. Kurlander, R. Goodwin, A. John Barrett, T. Fleisher, Richard W. Childs
Journal: Blood (2006)